There are 2789 resources available
864MO - Role of geriatric assessment in tailoring treatment of locally advanced head and neck cancer: The ELDERLY study
Presenter: Paolo Bossi
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
865MO - RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation
Presenter: Nandini Menon
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
1671MO - Impact of antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study
Presenter: Lawson Eng
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
LBA62 - Efficacy and safety of tanezumab in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy
Presenter: Marie Fallon
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
60MO - Gut microbiota and efficacy of immune-checkpoint inhibitors (ICIs) in patients (pts) with advanced solid tumor: SCRUM-Japan MONSTAR-SCREEN
Presenter: Kentaro Sawada
Session: Mini oral session - Translational research
Resources:
Abstract
Slides
Webcast
1760MO - Impact of immune checkpoint blockade therapy according to CD274 copy number alterations: A retrospective study in the ProfiLER cohort
Presenter: Khalil Hodroj
Session: Mini oral session - Translational research
Resources:
Abstract
Slides
Webcast
LBA52 - Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study
Presenter: Lin Shen
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA53 - Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
Presenter: Jianming Xu
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA54 - Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217)
Presenter: Alexander Stein
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA55 - Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen
Presenter: Eric Van Cutsem
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast